Cenicriviroc mesylate

N/A

Report date: 2024/01/16 15:43:03
NME

Base Information

Drug NameCenicriviroc mesylate
Drug Alias Name塞尼韦洛cenicrivirocumcenicrivirocCenicriviroc mesilateCCR5/CCR2 antagonist +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-C chemokine receptor type 2 antagonistsC-C chemokine receptor type 5 antagonists
TargetsC-C chemokine receptor type 5C-C chemokine receptor type 2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Cognition DisordersObesity +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[35] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaIND
Originator CompaniesTobira Therapeutics IncTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNational Center For Advancing Translational SciencesQuotient Sciences - Philadelphia LlcAbbvie Inc +[6] 
Inactive CompaniesAllergan PlcCharite University, Berlin, GermanyNovartis Pharma Ag +[4] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Cognition DisordersObesity +[7] 
Inactive IndicationsPrediabetic StateDiabetes Mellitus, Type 2Liver Cirrhosis +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG